Saturday 17 October 2026 Export CNTX’s income statement to Excel — free account

Context Therapeutics Inc.

In the quarter to June 2026, EPS fell 66.7% and free cash flow fell 20.6%, each against the same quarter a year earlier.

0.24 0.00 0.00%

Follow CNTX

Alert me

Market cap: $22.1M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 20.05%

Capital & Financial Ratios $m

Market Cap 22.09

Revenue —

Net Income (45.96)

Free Cash Flow (34.03)

Net Debt (42.99)

Current Ratio 5.81

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.60

Past 5Y EPS Growth —

This Y EPS Growth (21.34%)

Next Y EPS Growth 5.93%

Next Y revenue growth —

Next 5Y EPS Growth (12.77%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 26.77%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2018	Powerpack
2017	Powerpack
2016	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	14	94	66	43
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	16	98	68	46

	2023	2024	2025	Q'26
Payables	2	1	3	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	4	3	8	8

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	20.27%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(7)	—	—	—
’25	(5)	(6)	(7)	(9)	(26)
’24	(4)	(3)	(2)	(5)	(15)
’23	(6)	(5)	(3)	(7)	(21)
’22	(4)	(3)	(3)	(4)	(14)
’21	(2)	(2)	0	(5)	(9)
’20	0	0	(1)	0	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(7)	—	—	—
’25	(5)	(6)	(7)	(9)	(26)
’24	(4)	(3)	(2)	(5)	(15)
’23	(6)	(5)	(3)	(7)	(21)
’22	(4)	(3)	(3)	(4)	(14)
’21	(2)	(2)	0	(5)	(9)
’20	0	0	(1)	0	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.09)	(0.15)	—	—	—
’25	(0.05)	(0.09)	(0.10)	(0.14)	(0.38)
’24	(0.23)	(0.04)	(0.22)	0.00	(0.46)
’23	(0.40)	(0.31)	(0.37)	(0.42)	(1.50)
’22	(0.22)	(0.25)	(0.24)	(0.22)	(0.93)
’21	(2.25)	(14.17)	(4.00)	16.72	(3.69)
’20	0.08	0.68	(2.52)	—	3.23

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	2.56	0.60	0.47	0.89	0.49	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	10.87	2.83	1.69	2.75	1.55
People
People	Employees	—	—	—	—	—	7	9	5	12	15
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	0.00	—	—	—
	EBT	—	—	—	(6)	7	(10)	(15)	(24)	(27)	(36)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	(6)	7	(10)	(15)	(24)	(27)	(36)
	Depreciation	—	—	—	—	—	—	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	(0.58)	19.09	(3.69)	(0.93)	(1.50)	(0.46)	(0.38)
	Cash flow	—	—	—	(0.26)	(2.97)	(3.10)	(0.85)	(1.32)	(0.25)	(0.28)
	Capex	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	—	—	—	(0.26)	(2.97)	(3.10)	(0.85)	(1.32)	(0.25)	(0.28)
	Book value	—	—	—	(2.17)	(48.62)	17.03	2.18	0.74	1.63	0.64
	Shares, m	—	—	—	11	0	3	16	16	58	95
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(3)	(1)	(9)	(14)	(21)	(15)	(26)
	Capex	—	—	—	—	—	—	0	—	0	0
	Free cash flow	—	—	—	(3)	(1)	(9)	(14)	(21)	(15)	(26)
Balance, $m
Balance, $m	Working capital	—	—	—	(24)	(9)	48	35	12	95	60
	Total debt	—	—	—	22	6	—	0	—	—	—
	Net debt	—	—	—	22	6	(50)	(35)	(14)	(94)	(66)
	Shareholders’ equity	—	—	—	(24)	(17)	48	35	12	95	60
Returns, %
Returns, %	ROA	—	—	—	(4,668.52)	289.12	(40.40)	(33.24)	(88.71)	(46.81)	(43.36)
	ROIC	—	—	—	0.00	0.00	0.00	0.00	0.00	(2,235.80)	0.00
	ROE	—	—	—	31.23	(5.24)	(66.71)	(35.74)	(102.79)	(49.89)	(46.39)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BYSI BeyondSpring Inc.	$23.9M	— (loss-making)	— (loss-making)	+87.78% (above 0%: growing)	n/m	+35.78% (above 0%: growing)	100.00%	0.00%	Compare
CYAD Celyad SA	$23.8M	— (loss-making)	— (loss-making)	—	n/m	+78.72% (above 0%: growing)	0.00%	0.00%	Compare
PLRZ Polyrizon Ltd.	$23.7M	—	—	—	—	−744.51% (below 0%: shrinking)	—	—	Compare
IMMP Prima BioMed Ltd	$23.7M	— (loss-making)	—	—	n/m	−589,653.13% (below 0%: shrinking)	100.00%	(101.89%)	Compare
EVAX Evaxion A/S - Sponsored ADR	$23.4M	— (loss-making)	— (loss-making)	+14,590.20% (above 0%: growing)	n/m	−56.70% (below 0%: shrinking)	100.00%	0.00%	Compare
ESLA Estrella Immunopharma, Inc.	$23.3M	— (loss-making)	—	—	n/m	−329.19% (below 0%: shrinking)	—	0.00%	Compare
CNTX Context Therapeutics Inc.	$22.1M	— (loss-making)	—	—	n/m	−20.61% (below 0%: shrinking)	0.00%	0.00%
QNTM Quantum Biopharma Ltd.	$21.9M	— (loss-making)	— (loss-making)	—	n/m	+5.88% (above 0%: growing)	0.00%	0.00%	Compare
KYNB Kyntra Bio Inc	$21.7M	0.1×	— (loss-making)	−209.35% (below 0%: shrinking)	n/m	−131.50% (below 0%: shrinking)	100.14%	1,192.27%	Compare
Median of peers	$23.5M	—	—	+87.78%	—	−94.10%	100.00%	0.00%

All 614 Biotechnology stocks →

Context Therapeutics Inc. (CNTX) key facts

Context Therapeutics Inc. (CNTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CNTX traded at $0.24, a market capitalization of $22.1 million.
Return on equity was −46.4% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.